Moreover, targeting hepatic asprosin gene inhibition and GalNAc‐siRNAs to inhibit hepatic FABP5 both offer potential therapeutic benefits in the management of MASLD. This evidence concerns the gene FABP5 and metabolic dysfunction-associated steatotic liver disease.